These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. 18F-FLT PET for visualization of laryngeal cancer: comparison with 18F-FDG PET. Cobben DC; van der Laan BF; Maas B; Vaalburg W; Suurmeijer AJ; Hoekstra HJ; Jager PL; Elsinga PH J Nucl Med; 2004 Feb; 45(2):226-31. PubMed ID: 14960640 [TBL] [Abstract][Full Text] [Related]
6. Correlation of 18F-FLT and 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer. Yamamoto Y; Nishiyama Y; Ishikawa S; Nakano J; Chang SS; Bandoh S; Kanaji N; Haba R; Kushida Y; Ohkawa M Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1610-6. PubMed ID: 17530250 [TBL] [Abstract][Full Text] [Related]
7. Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study. Vera P; Bohn P; Edet-Sanson A; Salles A; Hapdey S; Gardin I; Ménard JF; Modzelewski R; Thiberville L; Dubray B Radiother Oncol; 2011 Jan; 98(1):109-16. PubMed ID: 21056487 [TBL] [Abstract][Full Text] [Related]
9. Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer. Thureau S; Chaumet-Riffaud P; Modzelewski R; Fernandez P; Tessonnier L; Vervueren L; Cachin F; Berriolo-Riedinger A; Olivier P; Kolesnikov-Gauthier H; Blagosklonov O; Bridji B; Devillers A; Collombier L; Courbon F; Gremillet E; Houzard C; Caignon JM; Roux J; Aide N; Brenot-Rossi I; Doyeux K; Dubray B; Vera P J Nucl Med; 2013 Sep; 54(9):1543-50. PubMed ID: 23918733 [TBL] [Abstract][Full Text] [Related]
10. Comparison of 18F-FLT PET and 18F-FDG PET in esophageal cancer. van Westreenen HL; Cobben DC; Jager PL; van Dullemen HM; Wesseling J; Elsinga PH; Plukker JT J Nucl Med; 2005 Mar; 46(3):400-4. PubMed ID: 15750150 [TBL] [Abstract][Full Text] [Related]
11. Comparison of (18)F-FLT PET and (18)F-FDG PET for preoperative staging in non-small cell lung cancer. Yamamoto Y; Nishiyama Y; Kimura N; Ishikawa S; Okuda M; Bandoh S; Kanaji N; Asakura M; Ohkawa M Eur J Nucl Med Mol Imaging; 2008 Feb; 35(2):236-45. PubMed ID: 17909790 [TBL] [Abstract][Full Text] [Related]
12. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. Higashi K; Ueda Y; Arisaka Y; Sakuma T; Nambu Y; Oguchi M; Seki H; Taki S; Tonami H; Yamamoto I J Nucl Med; 2002 Jan; 43(1):39-45. PubMed ID: 11801701 [TBL] [Abstract][Full Text] [Related]
13. Clinical relevance of imaging proliferative activity in lung nodules. Buck AK; Hetzel M; Schirrmeister H; Halter G; Möller P; Kratochwil C; Wahl A; Glatting G; Mottaghy FM; Mattfeldt T; Neumaier B; Reske SN Eur J Nucl Med Mol Imaging; 2005 May; 32(5):525-33. PubMed ID: 15599526 [TBL] [Abstract][Full Text] [Related]
14. Differential (18)F-FDG and (18)F-FLT Uptake on Serial PET/CT Imaging Before and During Definitive Chemoradiation for Non-Small Cell Lung Cancer. Everitt SJ; Ball DL; Hicks RJ; Callahan J; Plumridge N; Collins M; Herschtal A; Binns D; Kron T; Schneider M; MacManus M J Nucl Med; 2014 Jul; 55(7):1069-74. PubMed ID: 24833494 [TBL] [Abstract][Full Text] [Related]
15. Imaging cellular proliferation during chemo-radiotherapy: a pilot study of serial 18F-FLT positron emission tomography/computed tomography imaging for non-small-cell lung cancer. Everitt S; Hicks RJ; Ball D; Kron T; Schneider-Kolsky M; Walter T; Binns D; Mac Manus M Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1098-104. PubMed ID: 19386444 [TBL] [Abstract][Full Text] [Related]
16. Exploring spatial overlap of high-uptake regions derived from dual tracer positron emission tomography-computer tomography imaging using 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine in nonsmall cell lung cancer patients: a prospective pilot study. Liu J; Li C; Hu M; Lu J; Shi X; Xing L; Sun X; Fu Z; Yu J; Meng X Medicine (Baltimore); 2015 May; 94(17):e678. PubMed ID: 25929896 [TBL] [Abstract][Full Text] [Related]
17. FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology. Ryu JS; Choi NC; Fischman AJ; Lynch TJ; Mathisen DJ Lung Cancer; 2002 Feb; 35(2):179-87. PubMed ID: 11804691 [TBL] [Abstract][Full Text] [Related]
18. Repeatability of metabolically active volume measurements with 18F-FDG and 18F-FLT PET in non-small cell lung cancer. Frings V; de Langen AJ; Smit EF; van Velden FH; Hoekstra OS; van Tinteren H; Boellaard R J Nucl Med; 2010 Dec; 51(12):1870-7. PubMed ID: 21078791 [TBL] [Abstract][Full Text] [Related]
19. 3'-Deoxy-3'-18F-fluorothymidine as a proliferation imaging tracer for diagnosis of lung tumors: comparison with 2-deoxy-2-18f-fluoro-D-glucose. Yamamoto Y; Nishiyama Y; Ishikawa S; Gotoh M; Bandoh S; Kanaji N; Asakura M; Ohkawa M J Comput Assist Tomogr; 2008; 32(3):432-7. PubMed ID: 18520552 [TBL] [Abstract][Full Text] [Related]
20. Imaging of proliferation with 18F-FLT PET/CT versus 18F-FDG PET/CT in non-small-cell lung cancer. Yang W; Zhang Y; Fu Z; Yu J; Sun X; Mu D; Han A Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1291-9. PubMed ID: 20309686 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]